Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-DFC413 and safety and imaging properties of \[68Ga\]Ga-NNS309 in patients aged ≥ 18 years with solid tumors

Trial Details

NCT ID
NCT07261631
Phase
PHASE1
Sponsor
Novartis Pharmaceuticals
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • 68Ga-NNS309
  • 177Lu-DFC413
Locations (sample)
  • Montreal, Quebec, Canada|45.50884,-73.58781
  • Odense C, Denmark|55.40841,10.39538
  • Vandœuvre-lès-Nancy, France|48.66115,6.17114
  • Essen, Germany|51.45657,7.01228
  • Haifa, Israel|32.81303,34.99928

Key Eligibility Criteria

  • Adults ≥ 18 years with one of the following indications:
  • Locally advanced unresectable or metastatic PDAC, with disease progression following, or intolerance to cytotoxic therapy, unless patient was ineli…
  • Locally advanced unresectable or metastatic NSCLC without any actionable genomic alterations with disease progression following, or intolerance to …
  • Locally advanced unresectable or metastatic HR+/HER2- ductal and lobular breast cancer with disease progression following, or intolerance to, hormo…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →